Cue Health Selected by Minnesota Department of Health to Provide Statewide Telehealth to Treatment Services to all Minnesota Residents at No Cost
Cue Health (Nasdaq: HLTH) has partnered with the Minnesota Department of Health to offer a COVID-19 telehealth-to-treatment program at no cost. This service allows Minnesota residents who test positive for COVID-19 to consult healthcare professionals virtually and obtain prescriptions for treatment. The program provides same-day treatment access through local pharmacies, regardless of insurance status. Cue's COVID-19 test is renowned for its accuracy, with a 97.8% concordance rate with PCR tests, making it a critical tool in pandemic response.
- Partnership with Minnesota Department of Health enhances service offering.
- COVID-19 telehealth-to-treatment program provided at no cost to residents.
- Accurate COVID-19 test with 97.8% concordance rate with PCR tests.
- Accessible healthcare services regardless of insurance status.
- None.
In partnership with
With Cue, Minnesotans who test positive on any COVID-19 self test can consult virtually and on-demand with a healthcare professional to obtain a prescription for COVID-19 treatment at no cost, if they are medically indicated. Through the program, COVID-19 treatment is made available for same day pick-up or delivery from a local pharmacy. Cue’s telehealth to treatment services offered in partnership with MDH will be accessible at no cost to all
“Cue’s diagnostic platform has been deployed over the past two years across
Cue’s collaboration with the
Cue’s COVID-19 test was the first molecular diagnostic test available to consumers without a prescription and is the most accurate at-home COVID-19 test*, delivering results in 20 minutes to connected mobile devices. It detects all known COVID-19 variants of concern in people with or without symptoms. Cue is used in homes, in point-of-care settings, and by world-class organizations across the country, including
An independent study by
The telehealth-to-treatment service in
*#1 accuracy claim based on comparison of clinical study results submitted to the
About
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements”. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those related to the expected future diagnostic test menu and the factors discussed in the “Risk Factors” section of Cue’s Annual Report on Form 10-K for the year ended
Cue’s COVID-19 tests have not been FDA cleared or approved; but have been authorized by FDA and under an Emergency Use Authorization (EUA). These products have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005391/en/
MEDIA INQUIRIES
press@cuehealth.com
Source:
FAQ
What is the Cue Health COVID-19 telehealth program in Minnesota?
How does Cue Health's COVID-19 test compare to PCR tests?
Is the Cue Health COVID-19 treatment service available to everyone in Minnesota?